Arcturus Therapeutics Holdings/$ARCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
Ticker
$ARCT
Sector
Primary listing
Employees
175
Headquarters
Website
ARCT Metrics
BasicAdvanced
$326M
-
-$2.22
2.26
-
Price and volume
Market cap
$326M
Beta
2.26
52-week high
$24.17
52-week low
$8.04
Average daily volume
1.5M
Financial strength
Current ratio
5.901
Quick ratio
4.594
Long term debt to equity
9.925
Total debt to equity
11.67
Profitability
EBITDA (TTM)
-69.262
Gross margin (TTM)
-58.08%
Net profit margin (TTM)
-49.27%
Operating margin (TTM)
-59.43%
Effective tax rate (TTM)
0.36%
Revenue per employee (TTM)
$700,000
Management effectiveness
Return on assets (TTM)
-13.00%
Return on equity (TTM)
-24.57%
Valuation
Price to revenue (TTM)
2.663
Price to book
1.41
Price to tangible book (TTM)
1.41
Price to free cash flow (TTM)
-4.99
Free cash flow yield (TTM)
-20.04%
Free cash flow per share (TTM)
-2.405
Growth
Revenue change (TTM)
-25.47%
Earnings per share change (TTM)
-17.31%
3-year revenue growth (CAGR)
44.39%
3-year earnings per share growth (CAGR)
-29.25%
What the Analysts think about ARCT
Analyst ratings (Buy, Hold, Sell) for Arcturus Therapeutics Holdings stock.
Bulls say / Bears say
Interim Phase 2 data for ARCT-810 in OTC deficiency showed significant glutamine reductions to normal levels and stable ammonia, offering solid proof of concept and reducing risk for the liver program ahead of pivotal studies. (Business Wire)
Arcturus reported $253.4 million in cash and equivalents as of June 30, 2025, extending its cash runway into 2028 and supporting ongoing mRNA therapy development with no immediate need for new financing. (Business Wire)
Total operating expenses for Q2 2025 dropped by 44% year-over-year to $39.9 million, mainly due to lower manufacturing and clinical trial costs, improving capital efficiency. (Business Wire)
Revenue for Q2 2025 declined 43% year-over-year to $28.3 million due to reduced milestone and supply agreement activity under the CSL collaboration, shrinking near-term revenue streams. (Business Wire)
Arcturus incurred a net loss of $23.3 million for the six months ended June 30, 2025, reflecting persistent unprofitability with continued R&D and operating expenditures outpacing revenues. (Business Wire)
The Phase 2 cystic fibrosis program (ARCT-032) is not expected to complete enrollment until year-end 2025, delaying interim data readouts and deferring potential clinical catalysts into late 2025. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
ARCT Financial Performance
Revenues and expenses
ARCT Earnings Performance
Company profitability
ARCT News
AllArticlesVideos
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture
Benzinga2 days ago
Arcturus Crashes 55% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug
Investors Business Daily2 days ago
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
Business Wire2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcturus Therapeutics Holdings stock?
Arcturus Therapeutics Holdings (ARCT) has a market cap of $326M as of October 24, 2025.
What is the P/E ratio for Arcturus Therapeutics Holdings stock?
The price to earnings (P/E) ratio for Arcturus Therapeutics Holdings (ARCT) stock is 0 as of October 24, 2025.
Does Arcturus Therapeutics Holdings stock pay dividends?
No, Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders as of October 24, 2025.
When is the next Arcturus Therapeutics Holdings dividend payment date?
Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings (ARCT) has a beta rating of 2.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.